Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse , Human|
|Published species reactivity||Human , Mouse|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||Recombinant human p57Kip2 protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunohistochemistry (Paraffin) (IHC (P))||2-4 µg/ml|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||1:50-1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11309 targets p57Kip2 in WB, IHC (P) and IP applications and shows reactivity with Human and mouse samples.
The MA5-11309 immunogen is recombinant human p57Kip2 protein.
p57Kip2 (or CDKN1C) is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. The gene encoding human p57Kip2 is located on chromosome 11p15.5, a region implicated in both sporadic cancers, Wilm's tumor, and Beckwith-Wiedemann syndrome (BWS), a cancer syndrome, making it a tumor suppressor candidate. BWS is characterized by numerous growth abnormalities and an increased risk of childhood tumors. Several types of childhood tumors including Wilms' tumor, adrenocortical carcinoma and rhabdomyosarcoma display a specific loss of maternal 11p15 alleles, suggesting that genomic imprinting plays an important part. This region also contains two other imprinted genes, insulin-like growth factor II (IGF-II) and H19, both of which seem to be implicated in adrenal neoplasms.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Diagnostic utility of microsatellite genotyping for molar pregnancy testing.
MA5-11309 was used in immunohistochemistry to study the value of microsatellite genotyping for diagnostic testing of molar pregnancy
|Furtado LV,Paxton CN,Jama MA,Tripp SR,Wilson AR,Lyon E,Jarboe EA,Thaker HM,Geiersbach KB||Archives of pathology & laboratory medicine (137:55)||2013|
Combination of immunohistochemistry and ploidy analysis to assist histopathological diagnosis of molar diseases.
MA5-11309 was used in immunohistochemistry to study the use of immunohistochemistry and ploidy analysis to assist histopathological diagnosis of molar diseases
|Osterheld MC,Caron L,Chaubert P,Meagher-Villemure K||Clinical medicine. Pathology (1:61)||2011|
Androgenetic complete mole with trisomy 13: report of a case with microsatellite genotyping and review of the literature.
MA5-11309 was used in immunohistochemistry to investigate the genetic incident of trisomy 13 in a patient with a complete mole
|Dubé V,Chun K,Osborne R,Sherman C,Nofech-Mozes S,Ismiil N,Saad RS,Khalifa MA||Pathology, research and practice (206:776)||2010|
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
MA5-11309 was used in immunohistochemistry to study alterations in MiR-221 and MiR-222 expression in sporadic ovarian carcinoma
|Wurz K,Garcia RL,Goff BA,Mitchell PS,Lee JH,Tewari M,Swisher EM||Genes, chromosomes & cancer (49:577)||2010|
Early molar pregnancy: experience in a large abortion service.
MA5-11309 was used in immunohistochemistry to diagnose molar pregnancies early
|Paul M,Goodman S,Felix J,Lewis R,Hawkins M,Drey E||Contraception (81:150)||2010|
Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception.
MA5-11309 was used in immunohistochemistry to study the value of different tests for diagnosing molar and nonmolar products of conception
|Kipp BR,Ketterling RP,Oberg TN,Cousin MA,Plagge AM,Wiktor AE,Ihrke JM,Meyers CH,Morice WG,Halling KC,Clayton AC||American journal of clinical pathology (133:196)||2010|
The villous stromal constituents of complete hydatidiform mole differ histologically in very early pregnancy from the normally developing placenta.
MA5-11309 was used in immunohistochemistry to examine the histological manifestation and the pathogenesis of complete hydatidiform mole
|Kim KR,Park BH,Hong YO,Kwon HC,Robboy SJ||The American journal of surgical pathology (33:176)||2009|
SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis.
MA5-11309 was used in immunohistochemistry to study the role of bone morphogenetic protein receptor 1A in mice in cardiovascular development and organogenesis
|El-Bizri N,Guignabert C,Wang L,Cheng A,Stankunas K,Chang CP,Mishina Y,Rabinovitch M||Development (Cambridge, England) (135:2981)||2008|
Role of DNA content analysis and immunohistochemistry in the evaluation of the risk of unfavourable outcome in Wilms' tumours.
MA5-11309 was used in immunohistochemistry to study DNA content and immunohistochemistry in the evaluation of unfavourable outcome risk in Wilms' tumours
|Osterheld MC,Caron L,Meagher-Villemure K||Anticancer research (28:751)||2008|
P57KIP2 immunostaining and molecular cytogenetics: combined approach aids in diagnosis of morphologically challenging cases with molar phenotype and in detecting androgenetic cell lines in mosaic/chimeric conceptions.
MA5-11309 was used in immunohistochemistry to examine the diagnostic application of P57KIP2 immunostaining in molar pregnancies
|Hoffner L,Dunn J,Esposito N,Macpherson T,Surti U||Human pathology (39:63)||2008|
Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
MA5-11309 was used in immunohistochemistry to study the diagnostic and prognostic value of cell cycle regulators in differentiated thyroid cancer
|Melck A,Masoudi H,Griffith OL,Rajput A,Wilkins G,Bugis S,Jones SJ,Wiseman SM||Annals of surgical oncology (14:3403)||2007|
Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole.
MA5-11309 was used in immunohistochemistry to examine the diagnostic significance of p57KIP2 for complete hydatidiform mole
|Popiolek DA,Yee H,Mittal K,Chiriboga L,Prinz MK,Caragine TA,Budimlija ZM||Human pathology (37:1426)||2006|
Glomerular sclerosis in kidneys with congenital nephrotic syndrome (NPHS1).
MA5-11309 was used in immunohistochemistry to study the development of glomerular sclerosis in kidneys from infants with Finnish type congenital nephrotic syndrome
|Kuusniemi AM,Merenmies J,Lahdenkari AT,Holmberg C,Salmela K,Karikoski R,Rapola J,Jalanko H||Kidney international (70:1423)||2006|
E Proteins and Id2 converge on p57Kip2 to regulate cell cycle in neural cells.
MA5-11309 was used in immunohistochemistry to study the role of E-protein transcription factors and Id2 in cell cycle regulation in neural cells
|Rothschild G,Zhao X,Iavarone A,Lasorella A||Molecular and cellular biology (26:4351)||2006|
Diagnostic and pathogenetic significance of increased stromal apoptosis and incomplete vasculogenesis in complete hydatidiform moles in very early pregnancy periods.
MA5-11309 was used in immunohistochemistry to study the histologic features of complete hydatidiform moles during very early pregnancy
|Kim MJ,Kim KR,Ro JY,Lage JM,Lee HI||The American journal of surgical pathology (30:362)||2006|
Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism.
MA5-11309 was used in immunohistochemistry to study the molecular and immunohistochemical characteristics of the focal form of congenital hyperinsulinism
|Suchi M,MacMullen CM,Thornton PS,Adzick NS,Ganguly A,Ruchelli ED,Stanley CA||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (19:122)||2006|
Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
MA5-11309 was used in immunohistochemistry to investigate the changes of gene expression in intraductal papillary mucinous neoplasm
|Sato N,Matsubayashi H,Abe T,Fukushima N,Goggins M||Clinical cancer research : an official journal of the American Association for Cancer Research (11:4681)||2005|
p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses.
MA5-11309 was used in immunohistochemistry to evaluate the diagnostic significance of p57KIP2 immunohistochemistry in molar pregnancies
|Merchant SH,Amin MB,Viswanatha DS,Malhotra RK,Moehlenkamp C,Joste NE||Human pathology (36:180)||2005|
p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy.
MA5-11309 was used in immunohistochemistry to study whether immunohistochemical staining for p57KIP2 in gestational trophoblastic tumours can identify the type of causative pregnancy
|Sebire NJ,Rees HC,Peston D,Seckl MJ,Newlands ES,Fisher RA||Histopathology (45:135)||2004|
Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy.
MA5-11309 was used in immunohistochemistry to investigate the influence of Bcl-2 reduction on the progression and prognosis of human IgA nephropathy
|Qiu LQ,Sinniah R,I-Hong Hsu S||Journal of the American Society of Nephrology : JASN (15:79)||2004|
p57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles.
MA5-11309 was used in immunohistochemistry to investigate the prognostic usefulness of p57kip2 for hydatidiform moles
|Jun SY,Ro JY,Kim KR||Histopathology (43:17)||2003|
The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
MA5-11309 was used in western blot to study the role of the CDK inhibitor p57Kip2 in regulating cell cycle exit.
|Tury A,Mairet-Coello G,DiCicco-Bloom E||Cerebral cortex (New York, N.Y. : 1991) (21:1840)||2011|
cyclin-dependent kinase inhibitor 1C (p57, Kip2), cyclin-dependent kinase inhibitor p57, cyclin-dependent kinase inhibitor 1C
CDKI, KIP2, p57, Kip2, p57Kip2, WBS, BWCR, AL024410, BWS, p57(kip2)